Exploiting Synergy: Immune-based Combinations in the Treatment of Prostate Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2015 Jan 8

PMID 25566495

Citations 10

Authors

Mauricio Burotto

Nishith Singh

Christopher R Heery

James L Gulley

Ravi A Madan

Affiliations

Soon will be listed here.

Abstract

Cancer treatment is being revolutionized by the emergence of immunotherapies such as immune checkpoint inhibitors and therapeutic cancer vaccines. Prostate cancer is amenable to such therapeutic approaches. The improved understanding of the relationship between the immune system and tumors has allowed therapeutic targeting of immune checkpoints and tumor associated antigens to be developed. Furthermore, interventions used in prostate cancer are capable of impacting the immune system. As demonstrated by preclinical data and emerging clinical data, radiation therapy, anti-androgen therapy, and chemotherapy can be used with immunotherapies to obtain synergistic results. Current and future clinical trials will further investigate these principles as immunotherapeutics are combined with each other and standard therapies for optimal clinical utility.

Citing Articles

Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.

Koinis F, Xagara A, Chantzara E, Leontopoulou V, Aidarinis C, Kotsakis A Cells. 2022; 11(1).

PMID: 35011582 PMC: 8750906. DOI: 10.3390/cells11010020.

Harnessing the potential of multimodal radiotherapy in prostate cancer.

Philippou Y, Sjoberg H, Lamb A, Camilleri P, Bryant R Nat Rev Urol. 2020; 17(6):321-338.

PMID: 32358562 DOI: 10.1038/s41585-020-0310-3.

Sequential MR Image-Guided Local Immune Checkpoint Blockade Cancer Immunotherapy Using Ferumoxytol Capped Ultralarge Pore Mesoporous Silica Carriers after Standard Chemotherapy.

Choi B, Jung H, Yu B, Choi H, Lee J, Kim D Small. 2019; 15(52):e1904378.

PMID: 31697036 PMC: 7027959. DOI: 10.1002/smll.201904378.

Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model.

Lai X, Friedman A PLoS One. 2017; 12(5):e0178479.

PMID: 28542574 PMC: 5444846. DOI: 10.1371/journal.pone.0178479.

Immune Therapy for Prostate Cancer.

Yeku O, Slovin S Cancer J. 2016; 22(5):334-341.

PMID: 27749327 PMC: 5117426. DOI: 10.1097/PPO.0000000000000223.

References

Sweeney C . ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clin Adv Hematol Oncol. 2006; 4(8):588-90. View

Chambers C, Sullivan T, Allison J . Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 1998; 7(6):885-95. DOI: 10.1016/s1074-7613(00)80406-9. View

Garnett C, Schlom J, Hodge J . Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res. 2008; 14(11):3536-44. PMC: 2682419. DOI: 10.1158/1078-0432.CCR-07-4025. View

Kwilas A, Donahue R, Bernstein M, Hodge J . In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol. 2012; 2:104. PMC: 3434425. DOI: 10.3389/fonc.2012.00104. View

Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View

Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B . Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467(7319):1114-7. PMC: 3148940. DOI: 10.1038/nature09515. View

Roden A, Moser M, Tri S, Mercader M, Kuntz S, Dong H . Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004; 173(10):6098-108. DOI: 10.4049/jimmunol.173.10.6098. View

Campbell P, Yachida S, Mudie L, Stephens P, Pleasance E, Stebbings L . The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467(7319):1109-13. PMC: 3137369. DOI: 10.1038/nature09460. View

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2007; 8(1):59-73. DOI: 10.1038/nri2216. View

10.

Beer T, Bernstein G, Corman J, Glode L, Hall S, Poll W . Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011; 17(13):4558-67. DOI: 10.1158/1078-0432.CCR-10-3223. View

11.

NORTH R . Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982; 155(4):1063-74. PMC: 2186638. DOI: 10.1084/jem.155.4.1063. View

12.

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

13.

Small E, Tchekmedyian N, Rini B, Fong L, Lowy I, Allison J . A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007; 13(6):1810-5. DOI: 10.1158/1078-0432.CCR-06-2318. View

14.

Gameiro S, Ardiani A, Kwilas A, Hodge J . Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology. 2014; 3:e28643. PMC: 4091054. DOI: 10.4161/onci.28643. View

15.

Slovin S, Higano C, Hamid O, Tejwani S, Harzstark A, Alumkal J . Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013; 24(7):1813-1821. PMC: 3707423. DOI: 10.1093/annonc/mdt107. View

16.

Chakraborty M, Wansley E, Carrasquillo J, Yu S, Paik C, Camphausen K . The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res. 2008; 14(13):4241-9. PMC: 3407883. DOI: 10.1158/1078-0432.CCR-08-0335. View

17.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

18.

Andersen M, Schrama D, Straten P, Becker J . Cytotoxic T cells. J Invest Dermatol. 2006; 126(1):32-41. DOI: 10.1038/sj.jid.5700001. View

19.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

20.

Arlen P, Gulley J, Parker C, Skarupa L, Pazdur M, Panicali D . A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006; 12(4):1260-9. PMC: 1526707. DOI: 10.1158/1078-0432.CCR-05-2059. View